Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.39 |
| ▸ | TUBB | P07437 | 2/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361106 | 0.89 | TUBB4A (0.35) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1360080 | 0.88 | GRM5 (0.41) | MAPTLMNAHTTTDP1L3MBTL1 | |
| SCHEMBL1360001 | 0.88 | CYP1A2 (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1361656 | 0.87 | MAPT (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1363090 | 0.87 | SMN1; SMN2 (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1362240 | 0.87 | CYP1A2 (0.36) | TDP1L3MBTL1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL961476 | 0.86 | POLB (0.42) | MAPTLMNAHTTTDP1L3MBTL1 | |
| SCHEMBL962882 | 0.86 | MAPT (0.36) | MAPTLMNAHTTTDP1L3MBTL1 | |
| SCHEMBL1360093 | 0.85 | CYP1A2 (0.42) | MAPTTDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL1362394 | 0.85 | TDP1 (0.47) | MAPTLMNAHTTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | TUBB4A 1076/4885TUBB 1202/4885TUBA3C 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.